VTVT
vTv Therapeutics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
vTv Therapeutics has 3 disclosed suppliers and 5 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
SentenceIn February 2007, we entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the "Novo License Agreement") whereby we obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use, and commercialize products for the prevention, treatment, control, mitigation, or palliation of human or animal diseases or conditions.
SentenceAdditionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time.
VTVT 10-Kaccession 0001641489-26-000010
SentenceThe increase in research and development expenses during this period of approximately $6.3 million, or 54.7%, was primarily driven by (i) higher spending on cadisegliatin of $5.4 million, due to increases clinical studies, (ii) an increase in indirect costs of $2.6 million primarily due to increases in payroll and bonus costs and a $1.0 million Novo license milestone payment, partially offset by (iii) a decrease of $1.7 million in other projects primarily related to the write off of an aged accrual.
VTVT 10-Kaccession 0001641489-26-000010
SentenceOn June 22, 2021, vTv Therapeutics Inc. and Cantex Pharmaceuticals, Inc. ("Cantex") entered into a licensing agreement under which Cantex obtained exclusive worldwide rights to develop and commercialize azeliragon , vTv's novel antagonist of RAGE (the receptor for advanced glycation end products).
VTVT 10-Kaccession 0001641489-26-000010
SentenceSpecifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of cadisegliatin needed to conduct the trials.
VTVT 10-Kaccession 0001641489-26-000010
SentenceThe Company is the sponsor of this study that will be fully funded by G42 Investments.
VTVT 10-Kaccession 0001641489-26-000010
SentenceRevenue for the year ended December 31, 2024, includes a $1.0 million increase to the transaction price for the license performance obligation under the Newsoara License Agreement due to the satisfaction of a development milestone and recognition of deferred Huadong revenue.
VTVT 10-Kaccession 0001641489-26-000010
SentenceWe recently amended our license agreement with our partner, Newsoara BioPharma Co., Ltd. ("Newsoara"), to make it a global license to our PDE4 inhibitor ( HPP737 ), which included a $20.0 million upfront payment.
VTVT 10-Kaccession 0001641489-26-000010
Linked news
vTv Therapeutics Inc.
25.78
−0.60 · −2.29%
post 25.75 −0.09%